Cochrane Review Group

Urology

69 systematic reviews in Urology ask 1,000 questions. 19.6% have no studies to answer them, 19.8% rest on very low certainty evidence and 21.9% reach moderate or high certainty.

Reviews

Questions

1,000

current versions

No studies

19.6%

Moderate or high

21.9%

No studies 196 · 19.6%Ungraded 33 · 3.3%Very low 198 · 19.8%Low 354 · 35.4%Moderate 206 · 20.6%High 13 · 1.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Urology

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Topical corticosteroids vs placebo or no treatment Change in retractability score · boys up to 18 years old with phimosis Topical corticosteroids for treating phimosis in boys (2024) · Cochrane	no estimate extracted	2 studies · 177 participants	Very low
Serenoa repens in combination with other phytotherapy vs placebo or no intervention Quality of lifeMeasured by IPSS‐QoL score (range 0 to 6) · lower urinary tract symptoms due to benign prostatic hyperplasia Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement (2023) · Cochrane	no estimate extracted	2 studies · 265 participants	Very low
ESWL vs RIRS Quality of life MCID varies by instrument. · people (>14 years) with kidney stones Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde… (2023) · Cochrane	no estimate extracted	3 studies · 214 participants	Very low
ESWL vs RIRS Complications MCID: 3% absolute difference · people (>14 years) with kidney stones Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde… (2023) · Cochrane	RR 0.93 [0.63, 1.36]	13 studies · 1305 participants	Very low
Potassium paraaminobenzoate vs placebo Outcomes ( · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques… Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Degree of penile curvature · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	1 study · 103 participants	Very low
Injectional interferon alpha‐2B vs saline Discontinuation from treatment · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	RR 0.63 [0.22, 1.76]	1 study · 117 participants	Very low
Injectional nicardipine vs saline Outcomes ( · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Patient‐reported ability to have intercourse · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Quality of life · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Treatment‐related adverse effects · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	RR 2.82 [0.12, 66.62]	1 study · 62 participants	Very low

Reviews 69

Targeted therapy for metastatic renal cell carcinoma

Hofmann, F, Hwang, EC, et al. · Cochrane Database of Systematic Reviews · 2020

Urology

Thinnest evidence

Reviews 69

Targeted therapy for metastatic renal cell carcinoma

Abiraterone acetate in combination with androgen deprivation therapy compared to androgen deprivation therapy only for metastatic hormone‐sensitive prostate cancer

Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic hyperplasia

Alpha‐blockers after shock wave lithotripsy for renal or ureteral stones in adults

Retzius‐sparing versus standard robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer.

Early versus deferred standard androgen suppression therapy for advanced hormone‐sensitive prostate cancer

Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction

Perioperative nutrition for the treatment of bladder cancer by radical cystectomy

Medical and surgical interventions for the treatment of urinary stones in children

Hypofractionation for clinically localized prostate cancer

Robotic versus open radical cystectomy for bladder cancer in adults

Physical activity for lower urinary tract symptoms secondary to benign prostatic obstruction

Antimicrobial agents for preventing urinary tract infections in adults undergoing cystoscopy

Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome

Prostate MRI, with or without MRI‐targeted biopsy, and systematic biopsy for detecting prostate cancer

Ureteral stent versus no ureteral stent for ureteroscopy in the management of renal and ureteral calculi

Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia

Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia

Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma

Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical cystectomy

Primary cryotherapy for localised or locally advanced prostate cancer

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia

Alpha‐blockers as medical expulsive therapy for ureteral stones

Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia

Penile rehabilitation for postprostatectomy erectile dysfunction